Merz recently announced that the U.S. Food and Drug Administration (FDA) has cleared Cellfina’s new indication statement that shows the benefits of Cellfina last for five years, an increase from the previous three-year indication. The FDA clearance is supported by clinical data demonstrating treatment benefits in the appearance of cellulite on the buttocks and thighs of adult females through five years of observation, making it the longest-lasting cellulite treatment on the market cleared by the FDA.
The announcement about Cellfina is based on observations by an independent physician using before-and-after patient photographs at five years post-treatment. The results showed that after a single in-office treatment, 100 percent of follow-up patients still had noticeable improvements. Follow-up studies at one, three, and five years after a single in-office treatment showed sustained improvements. “This formal recognition from the FDA is a significant milestone for Cellfina customers, their patients and Merz," says Bob Rhatigan, CEO of Merz Americas. "Research shows women oftentimes feel defeated by their battle with cellulite, and we want to make sure our customers have an effective cellulite treatment option. Cellfina is the only cellulite treatment FDA-cleared for visible results that last five years. We are proud of this new indication, and it is a true testament to Cellfina’s efficacy and our commitment to bring customers the latest innovations in medical aesthetics.”
RELATED STORIES
Three Types of Microneedling Treatments Explained
Erchonia Receives First-Ever FDA 510(k) Pain Indication Using a Violet Laser
FDA Approves Allergan's CoolTone Device